论文部分内容阅读
目的:了解布地奈德混悬液雾化吸入治疗毛细支气管炎的临床疗效。方法:92例毛细支气管炎患儿随机分为治疗组和对照组各46例。治疗组在常规综合治疗基础上给予雾化吸入布地奈德混悬液1 mg,2次/d,疗程3～5 d,对照组常规综合治疗。结果:治疗组总有效率91.2%,对照组总有效率80.4%,两组总有效率比较差异有统计学意义(P<0.01)。治疗组喘憋症状消失时间、肺部哮鸣音消失时间及住院时间均比对照组短(P<0.01)。治疗组布地奈德气雾剂持续吸入3个月,随访1年,婴幼儿哮喘发病率(11.36%)较对照组(41.86%)明显下降(P<0.01)。结论:布地奈德混悬液以空气压缩泵雾化吸入治疗毛细支气管炎临床疗效确切,安全性高,优于单纯沙丁胺醇溶液雾化吸入。布地奈德持续吸入3个月可明显减少喘息的发作次数,可减少毛细支气管炎患儿发展成为哮喘的风险。
Objective: To understand the clinical efficacy of budesonide suspension inhalation for bronchiolitis. Methods: Ninety-two children with bronchiolitis were randomly divided into treatment group and control group with 46 cases each. The treatment group was given inhalation of budesonide suspension 1mg, 2 times / d on the basis of conventional comprehensive treatment for 3 ~ 5 days, and the control group was given conventional comprehensive treatment. Results: The total effective rate was 91.2% in the treatment group and 80.4% in the control group. The total effective rate was significantly different between the two groups (P <0.01). The disappearance of wheezing symptoms, disappearance of lung wheeze and hospital stay in the treatment group were shorter than those in the control group (P <0.01). In the treatment group, budesonide aerosol inhalation continued for 3 months. The incidence of asthma in infants and young children (11.36%) was significantly lower than that of the control group (41.86%) after one year follow-up (P <0.01). Conclusion: Budesonide suspension with air compression pump atomization inhalation treatment of bronchiolitis clinical curative effect is safe, higher than the simple salbutamol solution inhalation. Sustained inhalation of budesonide for 3 months can significantly reduce the number of episodes of wheezing and reduce the risk of asthma in children with bronchiolitis.